New vaccine trial aims to slow Parkinson's in early stages
NCT ID NCT06015841
Summary
This study is testing an experimental vaccine called ACI-7104.056 in people with early Parkinson's disease. The main goals are to check if the vaccine is safe and to see if it triggers an immune response against a harmful brain protein linked to Parkinson's. About 150 participants will receive either the vaccine or a placebo via injection over 74 weeks, followed by monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Hospital Universitari Vall D Hebron
Barcelona, Spain
-
Hospital Universitario De La Princesa
Madrid, Spain
-
Hospital Universitario Puerta De Hierro De Majadahonda
Majadahonda, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
-
Katholisches Klinikum Bochum GmbH
Bochum, Germany
-
King's College Hospital NHS Foundation Trust
London, United Kingdom
-
Northern Care Alliance NHS Foundation Trust
Salford, United Kingdom
-
Paracelsus-Kliniken Deutschland GmbH & Co. KGaA
Kassel, Germany
-
Policlinica Gipuzkoa
Donostia / San Sebastian, Spain
-
Re:Cognition Health Limited
London, United Kingdom
-
University Medical Centre Schleswig-Holstein
Kiel, Germany
Conditions
Explore the condition pages connected to this study.